Pharmacological characterization of metabotropic glutamate receptor 1 antagonist for the treatment of schizophrenia

被引：0
|
作者：
Maehara, Shunsuke [1 ]
机构：
[1] Mochida Pharmaceut Co Ltd, Biol Lab, Discovery Res, Shizuoka 4128524, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2013年 / 121卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：46P / 46P
页数：1
相关论文
共 50 条
  • [21] Metabotropic Glutamate Receptor 5 Binding in Individuals with Schizophrenia
    Akkus, Funda
    Treyer, Valerie
    Ametamey, Simon
    Burger, Cyrill
    Johayem, Anass
    Buck, Alfred
    Hasler, Gregor
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S541 - S542
  • [22] The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia
    Stansley, Branden J.
    Conn, P. Jeffrey
    CURRENT OPINION IN PHARMACOLOGY, 2018, 38 : 31 - 36
  • [23] EFFECT OF CFMTI, AN ALLOSTERIC METABOTROPIC GLUTAMATE RECEPTOR 1 ANTAGONIST WITH ANTIPSYCHOTIC ACTIVITY, ON Fos EXPRESSION IN REGIONS OF THE BRAIN RELATED TO SCHIZOPHRENIA
    Suzuki, G.
    Satow, A.
    Ohta, H.
    NEUROSCIENCE, 2010, 168 (03) : 787 - 796
  • [24] Pharmacological evidence for a metabotropic glutamate receptor heterodimer in neuronal cells
    Delgado, David Moreno
    Moller, Thor C.
    Ster, Jeanne
    Giraldo, Jesus
    Maurel, Damien
    Rovira, Xavier
    Scholler, Pauline
    Zwier, Jurriaan M.
    Perroy, Julie
    Durroux, Thierry
    Trinquet, Eric
    Prezeau, Laurent
    Rondard, Philippe
    Pin, Jean-Philippe
    ELIFE, 2017, 6
  • [25] In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists
    Suzuki, Gentaroh
    Tsukamoto, Naohiro
    Fushiki, Hiroshi
    Kawagishi, Aki
    Nakamura, Masayuki
    Kurihara, Hideki
    Mitsuya, Morihiro
    Ohkubo, Mitsuru
    Ohta, Hisashi
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (01): : 147 - 156
  • [26] Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia
    Dogra, Shalini
    Conn, P. Jeffrey
    MOLECULAR PHARMACOLOGY, 2022, 101 (05) : 275 - 285
  • [27] Metabotropic Glutamate Receptor and Endocannabinoid Signaling in the Prefrontal Cortex in Schizophrenia
    Volk, David
    Eggan, Stephen
    Lewis, David
    BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 13S - 13S
  • [28] Prospects for metabotropic glutamate 1 receptor antagonists in the treatment of neuropathic pain
    Schkeryantz, Jeffrey M.
    Kingston, Ann E.
    Johnson, Michael P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (11) : 2563 - 2568
  • [29] Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents:: Detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]
    Satow, Akio
    Maehara, Shunsuke
    Ise, Satoko
    Hikichi, Hirohiko
    Fukushima, Miyuki
    Suzuki, Gentaroh
    Kimura, Toshifumi
    Tanaka, Takeshi
    Ito, Satoru
    Kawamoto, Hiroshi
    Ohta, Hisashi
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 326 (02): : 577 - 586
  • [30] Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment
    Matosin, Natalie
    Frank, Elisabeth
    Deng, Chao
    Huang, Xu-Feng
    Newell, Kelly A.
    SCHIZOPHRENIA RESEARCH, 2013, 146 (1-3) : 170 - 176
12345